Literature DB >> 17182175

Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes.

Christina M Nagle1, Georgia Chenevix-Trench, Penelope M Webb, Amanda B Spurdle.   

Abstract

We evaluated the association between 21 polymorphisms in hormone and DNA repair pathway genes and survival among 454 Australian women diagnosed with invasive epithelial ovarian cancer. The cohort was followed for mortality using personal identifiers which were linked to state cancer registry records and the Australian National Death Index. The mean follow-up time after ovarian cancer diagnosis was 4.63 years (all women) and 8.07 years for the censored group (those alive or dead from non-ovarian cancer causes). Two hundred and eighty-eight (63%) ovarian cancer deaths occurred during the follow-up period. No association was observed for the vast majority of polymorphisms, but there was suggestive evidence for altered risk of ovarian cancer death associated with the CYP17 5'UTR C allele (HR 1.30; 95% CI=1.02-1.68, p= 0.04), and for the SRD5A2 V89L C allele (HR 0.79; 95% CI=0.62-1.01, p=0.06). These results are interesting given tentative evidence that both of these variants are also associated with increased predisposition to ovarian cancer in our extended Australian study, and in other published studies. However, given the marginal significance of these associations and the large number of tests performed, independent replication will be necessary to validate these novel findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182175     DOI: 10.1016/j.canlet.2006.11.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients.

Authors:  Andrea Mann; Estrid Hogdall; Susan J Ramus; Richard A DiCioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Bruce A J Ponder; Susanne Krüger Kjaer; Simon A Gayther; Deborah J Thompson; Paul D P Pharoah; Honglin Song
Journal:  Eur J Cancer       Date:  2008-08-22       Impact factor: 9.162

Review 2.  Revisiting the role of antiandrogen strategies in ovarian cancer.

Authors:  Dionysis Papadatos-Pastos; Konstantin J Dedes; Johann S de Bono; Stanley B Kaye
Journal:  Oncologist       Date:  2011-09-23

3.  An increased risk of ovarian cancer associated with polymorphism in BRCC5 gene in Caucasian populations.

Authors:  Hua Liang; Yan Li; Ruo-Yu Luo; Fu-Jin Shen
Journal:  Tumour Biol       Date:  2014-06-14

4.  Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.

Authors:  Prema Peethambaram; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Kimberly R Kalli; Elaine A Elliott; Ann L Oberg; Kristin L White; David N Rider; Gary L Keeney; Julie M Cunningham; Lynn C Hartmann; Ellen L Goode
Journal:  Int J Mol Epidemiol Genet       Date:  2011-05-02

Review 5.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.